The DisCoVeRy Trial: Remdesivir in COVID-19 – An Expensive Version of Tamiflu?
Marco Torres | Oct 18, 21
Background: Since the beginning of the pandemic, hundreds of trials have been performed looking at medications with the potential to be repurposed for use against COVID19. To date, no antiviral medications directed at SARS-CoV-2 have shown any convincing evidence of improvement. Treatments directed against the virus itself including ivermectin, hydroxychloroquine, and convalescent plasma have all fell well short of meaningful outcomes. Multiple previous trials (See discussion) have shown that remdesivir is associated with a shorter time to clinical improvement when the medication is started within 10 days of symptom onset. The largest trial on the topic  showed no benefit in mortality, initiation of ventilation or hospital length of stay. Due to the mixed previous results, there is no consensus on the use of remdesivir in COVID-19.